SCHEMBL269206

SCHEMBL269206

Cc1ccc(Cl)c(C[C@H](N)[C@H](O)Cc2ncccc2C(=O)NC(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
ANO1 Q5XXA6 8/20 0.37
RAB9A P51151 3/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
AHR P35869 1/20 0.35
EGFR P00533 1/20 0.35
P2RX7 Q99572 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
APEX1 P27695 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268030 1.00 SMN1; SMN2 (0.38) SMN1; SMN2ANO1RAB9AHPGDNPSR1
SCHEMBL269662 0.92 ANO1 (0.38) SMN1; SMN2ANO1RAB9AHPGDKMT2A
Hydrochloric Acid SCHEMBL270331 0.91 ANO1 (0.37) SMN1; SMN2ANO1RAB9AHPGDKMT2A
SCHEMBL267895 0.91 ANO1 (0.46) SMN1; SMN2ANO1EGFRP2RX7POLB
SCHEMBL268964 0.90 KDM4E (0.41) SMN1; SMN2ANO1RAB9AHPGDNPSR1
Hydrochloric Acid SCHEMBL270358 0.90 ANO1 (0.45) SMN1; SMN2ANO1P2RX7POLBAPEX1
Hydrochloric Acid SCHEMBL270538 0.90 ANO1 (0.45) SMN1; SMN2ANO1P2RX7POLBAPEX1
Hydrochloric Acid SCHEMBL268996 0.89 KDM4E (0.41) SMN1; SMN2ANO1RAB9AHPGDNPSR1
SCHEMBL267669 0.89 ANO1 (0.45) SMN1; SMN2ANO1NPSR1HTTTP53
SCHEMBL267788 0.89 ALOX5AP (0.38) SMN1; SMN2ANO1RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133907-B2 Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin ELI LILLY AND COMPANY (US) 2012-03-13 US disclosed
EP-1912946-B1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS LILLY CO ELI (US) 2009-05-27 EP disclosed
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors ELI LILLY AND COMPANY 2008-09-04 US disclosed
EP-1912946-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS Eli Lilly and Company (US) 2008-04-23 EP disclosed
WO-2007015767-A1 PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214616-A1 Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors DPP4, DPP3, DPP7 SMN1; SMN2 4330/4885ANO1 3344/4885RAB9A 3829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.